Press Releases from RESprotect GmbH (1 total)
RESprotect Elucidates The Mode Of Action Of Its Anti-Cancer Drug RP101: Binding …
Dresden/Germany - March 31, 2009 - RESprotect GmbH announced that its anti-cancer drug RP101 is the first small molecule known to bind to heat shock protein Hsp27 and modulate its effect. High levels of Hsp27 have been detected in leukemias, osteosarcomas, malignant melanomas and cancers of pancreatic, breast, ovarian, colon, liver, kidney, gastric, lung, endometrial and prostate origin. Especially high levels are observed in metastatic tissues. Hsp27 has significance in…
